Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 7/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 4/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20456716 | 0.78 | ERN1 (0.47) | KAT6AERN1CYP2A6 | |
| SCHEMBL27972145 | 0.76 | CYP2A6 (0.38) | KAT6ACYP2A6VCPCLK4DYRK1A | |
| SCHEMBL6657527 | 0.76 | ERN1 (0.45) | KAT6APIK3CDABL1EGFRHCK | |
| SCHEMBL9756866 | 0.72 | CYP2A6 (0.35) | KAT6ACYP2A6VCPCLK4DYRK1A | |
| SCHEMBL22657759 | 0.71 | AKR1C2 (0.47) | ERN1CYP2A6 | |
| SCHEMBL16193051 | 0.71 | NAPRT (0.40) | KAT6AVCPHDAC4 | |
| SCHEMBL20456721 | 0.71 | TGFBR1 (0.36) | KAT6APIK3CDABL1EGFRHCK | |
| SCHEMBL20456783 | 0.71 | ALOX5AP (0.39) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL13539329 | 0.69 | CYP2A6 (0.48) | KAT6APIK3CDPIK3CGCYP2A6CLK4 | |
| SCHEMBL29912312 | 0.69 | SLC40A1 (0.39) | ABL1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12084455-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-115991708-A | HIV inhibitor compounds | 吉利德科学公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-110536889-B | HIV inhibitor compounds | 吉利德科学公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-3577110-B1 | 8-OXETAN-3-YL-3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL SUBSTITUTED COMPOUNDS AS HIV INHIBITORS | GILEAD SCIENCES INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10752636-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752636-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10294234-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294234-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180258097-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-09-13 | — | — | US | disclosed |
| WO-2018145021-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018145021-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027055-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | KAT6A 256/4885PIK3CD 556/4885ABL1 195/4885 |
| US-20180258097-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | KAT6A 256/4885PIK3CD 556/4885ABL1 195/4885 |
| US-10752636-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | KAT6A 256/4885PIK3CD 556/4885ABL1 195/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | KAT6A 256/4885PIK3CD 556/4885ABL1 195/4885 |
| US-20190308983-A1 | HIV INHIBITOR COMPOUNDS | HASPIN, NFATC1, NHERF1 | KAT6A 424/4885PIK3CD 644/4885ABL1 190/4885 |
| US-12084455-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | KAT6A 256/4885PIK3CD 556/4885ABL1 195/4885 |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | SLC11A2, SLC6A15, NHERF1 | KAT6A 1066/4885PIK3CD 1203/4885ABL1 508/4885 |
| US-20250042910-A1 | HIV INHIBITOR COMPOUNDS | NFATC1, SAMHD1, CCR5 | KAT6A 256/4885PIK3CD 556/4885ABL1 195/4885 |
| US-10294234-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | KAT6A 256/4885PIK3CD 556/4885ABL1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.